CoChat

The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Background: Breast cancer exhibits significant molecular, pathological, and clinical heterogeneity. Current clinicopathological evaluation is imperfect for predicting outcome, which results in overtreatment for many patients, and for others, leads to death from recurrent disease. Therefore, additional criteria are needed to better personalize care and maximize treatment effectiveness and survival. Methods: To address these challenges, the Sweden Cancerome Analysis Network - Breast (SCAN-B) consortium was initiated in 2010 as a multicenter prospective study with longsighted aims to analyze breast cancers with next-generation genomic technologies for translational research in a population-based manner and integrated with healthcare; decipher fundamental tumor biology from these analyses; utilize genomic data to develop and validate new clinically-actionable biomarker assays; and establish real-time clinical implementation of molecular diagnostic, prognostic, and predictive tests. In the first phase, we focus on molecular profiling by next-generation RNA-sequencing on the Illumina platform. Results: In the first 3 years from 30 August 2010 through 31 August 2013, we have consented and enrolled 3,979 patients with primary breast cancer at the seven hospital sites in South Sweden, representing approximately 85% of eligible patients in the catchment area. Preoperative blood samples have been collected for 3,942 (99%) patients and primary tumor specimens collected for 2,929 (74%) patients. Herein we describe the study infrastructure and protocols and present initial proof of concept results from prospective RNA sequencing including tumor molecular subtyping and detection of driver gene mutations. Prospective patient enrollment is ongoing. Conclusions: We demonstrate that large-scale population-based collection and RNA-sequencing analysis of breast cancer is feasible. The SCAN-B Initiative should significantly reduce the time to discovery, validation, and clinical implementation of novel molecular diagnostic and predictive tests. We welcome the participation of additional comprehensive cancer treatment centers. Trial registration: ClinicalTrials.gov identifier NCT02306096.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13073-015-0131-9

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview of the SCAN-B infrastructure. Shown are the SCAN-B clinical (green boxes), laboratory (blue), and computational and analytical (orange) components. Solid black arrows indicate flow of material, and dashed black lines indicate flow of information. Enrollment and sampling of patients at time of preoperative (neoadjuvant) biopsy is not shown. ds, double-stranded; INCA, Swedish national breast cancer registry; TMA, tissue microarray.
Figure 1 Overview of the SCAN-B infrastructure. Shown are the SCAN-B clinical (green boxes), laboratory (blue), and computational and analytical (orange) components. Solid black arrows indicate flow of material, and dashed black lines indicate flow of information. Enrollment and sampling of patients at time of preoperative (neoadjuvant) biopsy is not shown. ds, double-stranded; INCA, Swedish national breast cancer registry; TMA, tissue microarray.CC BY · PubMed Central
Figure 2 Study demographics and clinical variables. (A) For the period 30 August 2010 to 31 August 2013, yearly (non-calendar) summary of the number of enrolled patients, the number of patients with preoperative blood sample collected, and number of patients with tumor specimen collected. (B-H) For the two complete calendar years 2011 and 2012 that could be matched to the INCA Swedish national breast cancer registry, (B) chart of all cases with a preoperative diagnosis of primary breast cancer within the catchment region divided into those that were accrued or not accrued. Comparison of baseline clinical variables between all eligible breast cancer patients, patients accrued, and patients accrued with tumor sample, for (C) estrogen receptor (ER) status, (D) progesterone receptor (PgR) status, (E) HER2 status, (F) age at diagnosis, (G) Nottingham histological grade (NHG), and (H) tumor size. †,‡ Significant differences were identified between all diagnoses and accrued with tumor specimen for NHG (P = 0.005) and tumor size (P <0.001), and between patients accrued and accrued with biopsy for NHG (P = 0.025) and tumor size (P <0.001).
Figure 2 Study demographics and clinical variables. (A) For the period 30 August 2010 to 31 August 2013, yearly (non-calendar) summary of the number of enrolled patients, the number of patients with preoperative blood sample collected, and number of patients with tumor specimen collected. (B-H) For the two complete calendar years 2011 and 2012 that could be matched to the INCA Swedish national breast cancer registry, (B) chart of all cases with a preoperative diagnosis of primary breast cancer within the catchment region divided into those that were accrued or not accrued. Comparison of baseline clinical variables between all eligible breast cancer patients, patients accrued, and patients accrued with tumor sample, for (C) estrogen receptor (ER) status, (D) progesterone receptor (PgR) status, (E) HER2 status, (F) age at diagnosis, (G) Nottingham histological grade (NHG), and (H) tumor size. †,‡ Significant differences were identified between all diagnoses and accrued with tumor specimen for NHG (P = 0.005) and tumor size (P <0.001), and between patients accrued and accrued with biopsy for NHG (P = 0.025) and tumor size (P <0.001).CC BY · PubMed Central
Figure 3 RNA sequencing and microarray analysis for population-based breast tumors. (A) Hierarchical clustering of 49 primary breast tumors (clustered columns) using the RNA-seq gene expression measurements and the PAM50 intrinsic gene signature (clustered rows). Clinical annotations for estrogen receptor (ER), progesterone receptor (PgR), and HER2 are indicated below the sample dendrogram, and PAM50 intrinsic subtyping is shown for classification using RNA-seq data as well as using microarray data generated from the same input RNA (90% concordant; results for Sørlie (92%) and Hu (96%) signatures are presented in Additional file 2: Figure S2). Genes of interest are highlighted in red, and relative expression level is indicated by the box color (see color key below the heatmap). For six tumor samples, technical replicates from the same RNA sources were performed for both RNA-seq and microarrays; plotted in (B) and (C) are representative examples comparing the fold-change for all RefSeq genes between two tumors (Y axis), and the fold-change between the replicated experiments for the same two tumors (X axis). Consistently, RNA-seq demonstrated values closer to the ideal line of identity and for a broader dynamic range. The +/- 2 fold-change (|log2| = 1) thresholds are indicated by blue dashed lines. (D) RNA-seq-derived expression level of ESR1, which encodes the ER alpha protein, is shown compared to the clinical ER IHC score for each of the 49 tumors. See Additional file 2: Figure S3 for corresponding plots for progesterone receptor and ERBB2 (HER2).
Figure 3 RNA sequencing and microarray analysis for population-based breast tumors. (A) Hierarchical clustering of 49 primary breast tumors (clustered columns) using the RNA-seq gene expression measurements and the PAM50 intrinsic gene signature (clustered rows). Clinical annotations for estrogen receptor (ER), progesterone receptor (PgR), and HER2 are indicated below the sample dendrogram, and PAM50 intrinsic subtyping is shown for classification using RNA-seq data as well as using microarray data generated from the same input RNA (90% concordant; results for Sørlie (92%) and Hu (96%) signatures are presented in Additional file 2: Figure S2). Genes of interest are highlighted in red, and relative expression level is indicated by the box color (see color key below the heatmap). For six tumor samples, technical replicates from the same RNA sources were performed for both RNA-seq and microarrays; plotted in (B) and (C) are representative examples comparing the fold-change for all RefSeq genes between two tumors (Y axis), and the fold-change between the replicated experiments for the same two tumors (X axis). Consistently, RNA-seq demonstrated values closer to the ideal line of identity and for a broader dynamic range. The +/- 2 fold-change (|log2| = 1) thresholds are indicated by blue dashed lines. (D) RNA-seq-derived expression level of ESR1, which encodes the ER alpha protein, is shown compared to the clinical ER IHC score for each of the 49 tumors. See Additional file 2: Figure S3 for corresponding plots for progesterone receptor and ERBB2 (HER2).CC BY · PubMed Central
Figure 4 Detection of mutations by RNA-seq. (A) Eighteen genes with at least one mutation (out of 90 genes screened) across the 49 population primary breast tumors are shown, in order of frequency (see totals and percentages to the right of each gene row). Mutant allele frequency is indicated by the box color (see key below matrix). All mutations are non-synonymous missense mutations except those indicated by F (frameshift) and X (nonsense). Tumor sample dendrogram is as in Figure 3A. Predicted mutant amino acids are shown for (B) PIK3CA which encodes the p110-alpha catalytic subunit of the phosphatidylinositol-4,5-bisphosphate 3-kinase oncogene, and (C) TP53 which encodes the tumor suppressor TP53.
Figure 4 Detection of mutations by RNA-seq. (A) Eighteen genes with at least one mutation (out of 90 genes screened) across the 49 population primary breast tumors are shown, in order of frequency (see totals and percentages to the right of each gene row). Mutant allele frequency is indicated by the box color (see key below matrix). All mutations are non-synonymous missense mutations except those indicated by F (frameshift) and X (nonsense). Tumor sample dendrogram is as in Figure 3A. Predicted mutant amino acids are shown for (B) PIK3CA which encodes the p110-alpha catalytic subunit of the phosphatidylinositol-4,5-bisphosphate 3-kinase oncogene, and (C) TP53 which encodes the tumor suppressor TP53.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Research works printed but not linked: 1

  1. Gene Expression Omnibus. Available at: http://www.ncbi.nlm.nih.gov/geo/.

Cited by

See all 281

Metadata

Authors
Saal, L. H., Vallon-Christersson, J., Häkkinen, J., Hegardt, C., Grabau, D., Winter, C., Brueffer, C., Tang, M.-H. E., Reuterswärd, C., Schulz, R., Karlsson, A., Ehinger, A., Malina, J., Manjer, J., Malmberg, M., Larsson, C., Rydén, L., Loman, N., & Borg, Å.
Affiliations
  • Lund University (SE)
  • Skåne University Hospital (SE)
Corresponding author
Borg, Åke
Venue
Genome Medicine
Published
2015-02-02
Volume
7
Issue
1
Pages
20-20
ISSN
1756-994X (ISSN-L)
OpenAlex
W2115528316
Cited by
255
References
46
Citations by year
2026: 28 · 2025: 39 · 2024: 54 · 2023: 36 · 2022: 18 · 2021: 28 · 2020: 16 · 2019: 8 · 2018: 7 · 2017: 8 · 2016: 12 · 2015: 1
FWCI
3.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Genome Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion, other-oa)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders
  • Stiftelsen för Strategisk Forskning
  • VINNOVA
  • Cancerfonden
  • Lunds Universitet
  • Gunnar Nilssons Cancerstiftelse
  • Knut och Alice Wallenbergs Stiftelse
  • Vetenskapsrådet
  • Fru Berta Kamprads Stiftelse
  • Institut National Du Cancer
  • Centralsjukhuset Kristianstad
  • Region Skåne
  • Skånes universitetssjukhus
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords
breast cancer, driver mutations, RNA sequencing, prognostic and predictive biomarkers, precision oncology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. https://app.cochat.ai/papers/10.1186/s13073-015-0131-9
The paper
Saal, L. H., Vallon-Christersson, J., Häkkinen, J., Hegardt, C., Grabau, D., Winter, C., Brueffer, C., Tang, M.-H. E., Reuterswärd, C., Schulz, R., Karlsson, A., Ehinger, A., Malina, J., Manjer, J., Malmberg, M., Larsson, C., Rydén, L., Loman, N., & Borg, Å. (2015). The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Medicine. https://doi.org/10.1186/s13073-015-0131-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.